Lakewood-Amedex Biotherapeutics Inc. - What You Need to Know

Thinking about buying Lakewood-Amedex stock? Biotech investments can be a wild ride. Here is a plain-English breakdown of what you are looking at.

1. What does this company do?

Lakewood-Amedex is a biotech company focused on fighting antibiotic-resistant "superbugs." They are developing a unique class of drugs called Bisphosphocins®, which kill bacteria by breaking down their outer cell walls.

Their lead project, Nu-3, is a topical gel designed to treat infected diabetic foot ulcers. They are also researching applications for their technology in treating lung infections and preventing bacterial buildup on medical devices like catheters.

2. How do they make money?

Currently, they don’t. They are in the research phase and have zero revenue from product sales. The company relies entirely on outside funding to pay for expensive clinical trials. For the nine months ending September 30, 2025, they reported a net loss of approximately $3.1 million. Their value is based entirely on their intellectual property and the hope that the FDA will eventually approve their drugs for commercial use.

3. How are they going public?

They are using a "Direct Listing" on the Nasdaq under the ticker $LABT. Unlike a traditional IPO, there are no investment banks involved to set an initial price or stabilize the stock. Because there is no "bank cushion" to support the price, the stock may be significantly more volatile once trading begins.

4. The Financial Reality

The company is in a tight financial position. As of September 30, 2025, they held only $658,000 in cash, while their debts totaled about $2.2 million. Because clinical trials are incredibly expensive, they will need to raise more capital soon. They will likely do this by issuing more shares, which would dilute existing shareholders—meaning your ownership percentage would shrink and potentially lower the value of your investment.

5. What are the main risks?

• Clinical Trial Uncertainty: Biotech is an "all or nothing" game. Even promising drugs often fail in later, larger trials. Additionally, some of their studies are "open-label," meaning patients and doctors know who is receiving the drug; this can introduce bias and make results appear more favorable than they might be in a blinded study.
• Operational Hurdles: The company has never brought a drug to market. They lack the established sales and marketing infrastructure needed to succeed. Even with FDA approval, they would still face the massive challenge of convincing doctors to prescribe their products and insurance companies to cover them.
• Resource Constraints: With very little cash on hand, the company must carefully choose which projects to fund. If they prioritize the wrong project, they may run out of money before they can reach a breakthrough.
• Logistics: Their products may require specific storage conditions, such as refrigeration. If their supply chain cannot maintain these requirements, the drugs could become ineffective.

Is this right for you?

This is not a "set it and forget it" investment. Between the lack of revenue, the high burn rate, and the significant hurdles required to bring a drug to market, this is a high-stakes gamble.

Before you buy:

• Check the cash: Keep an eye on their quarterly reports to see how quickly they are burning through their remaining funds.
• Watch for dilution: If they announce a new stock offering, understand that it will likely impact the share price.
• Only invest what you can afford to lose: Given the speculative nature of early-stage biotech, this should be considered a high-risk portion of a portfolio, not a foundation.

Disclaimer: I am an AI, not a financial advisor. Investing in stocks is risky. Always do your own research or talk to a professional before investing.